(Q37424886)

20 August 2017

1 reference

title

Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis (English)

1 reference

20 August 2017

1 reference

1 reference

Victor H Jimenez-Zepeda

series ordinal

1

1 reference

20 August 2017

Virginia J Dominguez-Martinez

series ordinal

2

1 reference

20 August 2017

publication date

27 March 2009

1 reference

International Journal of Hematology

20 August 2017

published in

1 reference

20 August 2017

volume

89

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

259-268

1 reference

Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia

20 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-009-0288-3

Anti-tumour activity of bisphosphonates in human myeloma cells.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-009-0288-3

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

12 December 2020

Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications

1 reference

12 December 2020

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

1 reference

12 December 2020

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

12 December 2020

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

1 reference

12 December 2020

Plasma cell leukemia (PCL): A report on 15 patients

1 reference

12 December 2020

The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

1 reference

12 December 2020

Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics

1 reference

12 December 2020

Genetics and cytogenetics of multiple myeloma: a workshop report

1 reference

12 December 2020

Primary plasma cell leukemia occuring in the young

1 reference

12 December 2020

Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?

1 reference

12 December 2020

Analysis of p73 and p53 gene deletions in multiple myeloma

1 reference

12 December 2020

Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia

1 reference

12 December 2020

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

1 reference

12 December 2020

Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia

1 reference

12 December 2020

1 reference

12 December 2020

Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma

1 reference

12 December 2020

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

1 reference

12 December 2020

Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia

1 reference

12 December 2020

Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization.

1 reference

12 December 2020

Acquired activated protein C resistance and thrombosis in multiple myeloma patients

1 reference

12 December 2020

Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration

1 reference

12 December 2020

Efficacy and safety of bortezomib in patients with plasma cell leukemia

1 reference

12 December 2020

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

1 reference

12 December 2020

Plasma cell leukemia: a rare condition.

1 reference

12 December 2020

Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?

1 reference

12 December 2020

Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia

1 reference

12 December 2020

Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors

1 reference

12 December 2020

Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hé

1 reference

12 December 2020

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

12 December 2020

Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?

1 reference

12 December 2020

Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature

1 reference

12 December 2020

K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements.

1 reference

12 December 2020

Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia

1 reference

12 December 2020

N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma

1 reference

12 December 2020

Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies

1 reference

12 December 2020

Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation

1 reference

12 December 2020

Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma

1 reference

12 December 2020

Clinical and biologic implications of recurrent genomic aberrations in myeloma

1 reference

12 December 2020

Primary plasma cell leukemia presented as progressive paraplegia: a case report

1 reference

12 December 2020

Fludarabine and plasma cell leukemia

1 reference

12 December 2020

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

1 reference

12 December 2020

Current standards for first-line therapy of multiple myeloma

1 reference

12 December 2020

Thirty patients with primary plasma cell leukemia: a single center experience

1 reference

12 December 2020

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

12 December 2020

Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy.

1 reference

12 December 2020

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

1 reference

12 December 2020

Genetic aberrations and survival in plasma cell leukemia

1 reference

12 December 2020

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.

1 reference

12 December 2020

Stem-cell transplantation for multiple myeloma in the era of novel drugs

1 reference

12 December 2020

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

1 reference

12 December 2020

Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation

1 reference

12 December 2020

p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2.

1 reference

12 December 2020

Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment

1 reference

12 December 2020

Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment

1 reference

12 December 2020

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

1 reference

12 December 2020

Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

12 December 2020

Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report

1 reference

12 December 2020

Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

1 reference

12 December 2020

Primary plasma cell leukaemia

1 reference

12 December 2020

Increased expression of natural-killer-associated and activation antigens in multiple myeloma

1 reference

12 December 2020

Treatment of plasma cell dyscrasias with lenalidomide

1 reference

12 December 2020

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

12 December 2020

Clinical significance of TP53 mutation in myeloma

1 reference

12 December 2020

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

1 reference

12 December 2020

A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique

1 reference

12 December 2020

Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center

1 reference

12 December 2020

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

1 reference

12 December 2020

Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia

1 reference

12 December 2020

Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia

1 reference

12 December 2020

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

12 December 2020

The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing

1 reference

12 December 2020

Primary plasma cell leukemia in a 30-year-old woman

1 reference

12 December 2020

1 reference

12 December 2020

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

1 reference

12 December 2020

VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia

1 reference

12 December 2020

Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling

1 reference

12 December 2020

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

1 reference

12 December 2020

Plasma cell leukemia. Report on 17 cases

1 reference

12 December 2020

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

1 reference

12 December 2020

Primary plasma cell leukaemia: a report of 18 cases

1 reference

12 December 2020

Treatment of plasma cell leukaemia and resistant/relapsed multiple myeloma with vincristine, mitoxantrone and dexamethasone (VMD protocol)

1 reference

12 December 2020

Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

12 December 2020

Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia

1 reference

12 December 2020

Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia

1 reference

12 December 2020

Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma

1 reference

12 December 2020

Primary plasma cell leukemia--a comprehensive analysis of 44 cases

1 reference

12 December 2020

Plasma cell leukemia with iga paraproteinemia and hyperviscosity

1 reference

12 December 2020

Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity

1 reference

12 December 2020

10.1007/S12185-009-0288-3

Identifiers

DOI

1 reference

20 August 2017

1 reference